Navigation Links
Minnesota partnership advances potential MS therapy
Date:4/17/2008

ROCHESTER/MINNEAPOLIS, Minn. A production laboratory founded by the Minnesota Partnership has transferred its first potential therapy a medication for multiple sclerosis to a processing plant in Minnesota. This step will complete purification of material to fully enable translation from preclinical to clinical development.

The antibody known as rHIgM22, developed at Mayo Clinic, was produced and purified in the Biotherapeutic Protein Production Laboratory created by a Partnership infrastructure award in 2006. This laboratory was developed within the Molecular and Cellular Therapeutics Facility on the St. Paul campus of the University of Minnesota. The therapy is under license to Acorda Therapeutics, Inc. (NASDAQ: ACOR), which is supporting the development of this potential therapy. This includes the Minnesota Partnerships transfer of remaining production and purification to Biovest, Inc., in Minneapolis.

The preclinical success and the promise of this program to date have only enhanced our commitment to the continued advancement of this potential new therapy for people with multiple sclerosis, says Ron Cohen, M.D., Acorda president and CEO. The Partnership has provided a mechanism for academic and commercial institutions to work together effectively in the early stages of developing a promising and innovative therapeutic approach to a very challenging condition.

The importance of the antibody as a promoter of myelin repair (remyelination) was recognized in studies using experimental animal models of multiple sclerosis. The studies were directed by Moses Rodriguez, M.D., a Mayo Clinic neurologist. Multiple sclerosis is a progressive disease, caused by damage to the myelin sheath that surrounds nerves. It can affect the brain and the spinal cord, leaving patients permanently disabled. The rHIgM22 antibody initiates the re-growth or repair of the damaged myelin sheath but has yet to be tested in patients.

The initial synthetic production of the therapeutic antibody was developed in the laboratory of Larry Pease, Ph.D., chair of immunology at Mayo. Early stage process development was also performed in collaboration with Acorda Therapeutics. The Partnership facility subsequently developed production of the antibody into a validated process that can be used to produce antibody for patient studies. John Wagner, M.D., at the University of Minnesota, and Dr. Pease were the principal investigators on the Minnesota Partnership grant. The grant established the protein production facility with the mission of providing good manufacturing (GMP) technical support to investigators at the University of Minnesota and Mayo Clinic to move laboratory advancements into clinical trials. The developmental work on this antibody at the protein production facility was funded by philanthropic gifts from the Eugene Applebaum Family Foundation, the Conrad N. Hilton Foundation, and anonymous benefactors.

The Minnesota Partnership was instrumental in providing the infrastructure to develop this monoclonal antibody to this point, says Dr. Pease. This antibody would not be headed into clinical studies or toward commercialization otherwise.

This is exactly what the Partnership is intended to do, says program director Eric Wieben, Ph.D. That is to promote interactions between the two leading medical research institutions in Minnesota and to accelerate medical discoveries that can be commercialized for the benefit of patients while improving our states economy.


'/>"/>

Contact: Nick Hanson
hans2853@umn.edu
612-624-2449
University of Minnesota
Source:Eurekalert

Related medicine news :

1. Securians Minnesota Life Continues to Climb Group Life Rankings
2. Fresh Air Campaign to Showcase Minnesotans Love of Smoke-Free Air
3. Four Minnesota Hospitals Rate High For Patient Safety and Quality
4. First-in-the-Nation Health Care Billing Policy Announced in Minnesota
5. Help is Available for Smokers Who Want to Quit as Minnesotas Smoke-Free Law Takes Effect Oct. 1
6. Maryland, Minnesota Go Smoke-free Oct. 1 - Pennsylvania Overdue in Following Suit
7. New National Medicaid Study: Minnesota Under Funds Seniors Nursing Home Care $167 Million Annually
8. Blue Cross and Partners to Host Combat Stress Conference for Minnesotas Health Care Professionals
9. TV Documentary Examines Three Decades of Tobacco Politics, Policies and People in Minnesota
10. Minneapolis Hosts National Conference on Tobacco or Health October 24-26 on Heels of Minnesotas Statewide, Smoke-Free Law
11. Mayo Clinic Calls for Thorough Review of Canadian Pacifics Acquisition of the Dakota, Minnesota & Eastern Railroad
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology: